USP12-AS1: A Potential Drug Target and Biomarker (G100874070)

USP12-AS1: A Potential Drug Target and Biomarker

USP12-AS1, also known as USP12, is a protein that is expressed in various tissues throughout the body, including the brain, lungs, heart, kidneys, and gastrointestinal tract. It is a member of the USP family of proteins, which are known for their role in cell signaling and division. USP12-AS1 has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The USP12-AS1 protein is composed of 214 amino acid residues and has a calculated molecular weight of 23.5 kDa. It is expressed in a variety of tissues, including the brain, where it is found in the endoplasmic reticulum, the photoreceptor neurons of the retina, and the heart. It is also expressed in the lungs, kidneys, and gastrointestinal tract, and has been shown to be involved in various physiological processes, including cell signaling, cell division, and tissue repair.

One of the key functions of USP12-AS1 is its role in cell signaling. It is a negative regulator of the RhoA GTPase, which is a protein that plays a role in cell signaling and division. USP12-AS1 functions as a negative regulator by binding to the RhoA protein and preventing it from activating the RhoA GTPase. This interaction between USP12-AS1 and RhoA GTPase is important for maintaining the integrity of the cytoskeleton and cell signaling.

In addition to its role in cell signaling, USP12-AS1 is also a potential biomarker for various diseases. Its expression has been observed in a variety of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. It has also been shown to be expressed in various types of cancer, including breast, ovarian, and colorectal cancer. These findings suggest that USP12-AS1 may be a useful biomarker for these diseases and that it may also be a potential drug target.

One of the potential benefits of USP12-AS1 as a drug target is its ability to modulate the activity of other proteins. USP12-AS1 has been shown to interact with a variety of proteins, including RhoA GTPase, Myosin, and actinin. This interaction with these proteins suggests that USP12-AS1 may be a useful target for drugs that modulate the activity of these proteins.

Another potential benefit of USP12-AS1 as a drug target is its role in the development and progression of various diseases. USP12-AS1 has been shown to be involved in the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. It has also been shown to be involved in the development and progression of various types of cancer, including breast, ovarian, and colorectal cancer. These findings suggest that USP12-AS1 may be a useful target for drugs that target these diseases.

In conclusion, USP12-AS1 is a protein that is expressed in various tissues throughout the body and has been identified as a potential drug target and biomarker for various diseases. Its role in cell signaling and its expression in various tissues make it an attractive target for drugs that modulate its activity. Further research is needed to fully understand the role of USP12-AS1 in disease and to develop effective treatments.

Protein Name: USP12 Antisense RNA 1

The "USP12-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about USP12-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

USP12-DT | USP13 | USP14 | USP15 | USP16 | USP17L1 | USP17L10 | USP17L11 | USP17L12 | USP17L13 | USP17L14P | USP17L15 | USP17L17 | USP17L18 | USP17L2 | USP17L20 | USP17L21 | USP17L24 | USP17L25 | USP17L26 | USP17L27 | USP17L29 | USP17L3 | USP17L5 | USP17L6P | USP17L7 | USP17L8 | USP17L9P | USP18 | USP19 | USP2 | USP2-AS1 | USP20 | USP21 | USP22 | USP24 | USP25 | USP26 | USP27X | USP27X-DT | USP28 | USP29 | USP3 | USP3-AS1 | USP30 | USP30-AS1 | USP31 | USP32 | USP32P1 | USP32P2 | USP32P3 | USP33 | USP34 | USP35 | USP36 | USP37 | USP38 | USP39 | USP4 | USP40 | USP41 | USP42 | USP43 | USP44 | USP45 | USP46 | USP46-DT | USP47 | USP48 | USP49 | USP5 | USP50 | USP51 | USP53 | USP54 | USP6 | USP6NL | USP6NL intronic transcript 1 (non-protein coding), transcript variant 1 | USP7 | USP8 | USP8P1 | USP9X | USP9Y | USPL1 | UST | UTF1 | UTP11 | UTP14A | UTP14C | UTP15 | UTP18 | UTP20 | UTP23 | UTP25 | UTP3 | UTP4 | UTP6 | UTRN | UTS2 | UTS2B